B
Bull
Bull · 25%KRON
$1.31
情境價格
$0.880
+0.013 (+1.49%)收盤時
Loading chart…
- High
- 0.881
- Open
- 0.881
- VWAP
- 0.88
- Vol
- 54.09K
- Mkt Cap
- 72.11M
- Low
- 0.870
- Amount
- 47.44K
- EV/EBITDA, TTM
- 0.62
Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases. Its product candidates include KB-9558 and KB-7898. KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN, is in preclinical development for the treatment of multiple myeloma and human papillomavirus (HPV)-driven tumors. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. KB-7898 is a p300 KAT inhibitor for the treatment of Sjogren’s disease, a chronic autoimmune disease that is characterized by the production of autoantibodies, chronic inflammation and lymphocytic infiltration of the exocrine glands that lead to uncomfortable dryness symptoms, known as sicca.
估值指標
The current forward P/E ratio for Kronos Bio Inc (KRON) is -0.71, compared to its 5-year average forward P/E of -1.50.
Alphio AI Price Scenarios for KRON
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
事件時間軸
資訊
7.005-28PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KRON, AXL, TASK, STRR on Behalf of Shareholders
7.005-18GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AXL, KRON, PRA, SWTX on Behalf of Shareholders
7.005-15GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders
8.505-15GlobenewswireBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (Nasdaq - KRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Longevity Health Holdings, Inc. (Nasdaq - XAGE), Southern States Bancshares, Inc. (Nasdaq - SSBK)
7.005-06PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, PPBI, COEP on Behalf of Shareholders
KRON FAQ — answered by Alphio AI
Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases. Its product candidates include KB-9558 and KB-7898. KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN, is in preclinical development for the treatment of multiple myeloma and human papillomavirus (HPV)-driven tumors. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. KB-7898 is a p300 KAT inhibitor for the treatment of Sjogren’s disease, a chronic autoimmune disease that is characterized by the production of autoantibodies, chronic inflammation and lymphocytic infiltration of the exocrine glands that lead to uncomfortable dryness symptoms, known as sicca. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。